EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitSystematische ÜbersichtOpen Access · CC BY-NC-ND 4.0

Asciminib as first-line therapy in chronic myeloid leukemia: a systematic review

Jae Joon Han, Jeong-Ok Lee, Kyoung Ha Kim, Sung-Eun Lee, Sang Kyun Sohn, Chul Won Jung, Hawk Kim, Korean Society of Hematology Chronic Myeloid Leukemia Working Party

Blood Research · 2026-12 · 61 (1)

DOI: 10.1007/s44313-026-00153-2 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Blood Research, online erschienen am 15.07.2026. Verfasst von Jae Joon Han und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Ewha Womans University Seoul Hospital, Ewha Womans University College of Medicine, Seoul, Republic of Korea. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

AsciminibBCR::ABL1Chronic myeloid leukemiaFirst-line therapyMolecular responseTyrosine kinase inhibitor

Autor:innen und Institutionen

  • Division of Hematology, Ewha Womans University Seoul Hospital, Ewha Womans University College of Medicine, Seoul, Republic of Korea.
  • Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Republic of Korea.
  • Division of Hematology and Oncology, Department of Internal Medicine, Soonchunhyang University Hospital, Seoul, Republic of Korea.
  • Department of Hematology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
  • Division of Hematology-Oncology, Department of Internal Medicine, Kyungpook National University Hospital, Daegu, Republic of Korea.
  • Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.

Zitieren

APA

Han, J. J., Lee, J. O., Kim, K. H., Lee, S. E., Sohn, S. K., Jung, C. W., Kim, H., & Korean Society of Hematology Chronic Myeloid Leukemia Working Party (2026). Asciminib as first-line therapy in chronic myeloid leukemia: a systematic review. Blood Research, 61(1). https://doi.org/10.1007/s44313-026-00153-2

Vancouver

Han JJ, Lee JO, Kim KH, Lee SE, Sohn SK, Jung CW, et al. Asciminib as first-line therapy in chronic myeloid leukemia: a systematic review. Blood Research. 2026;61(1). doi:10.1007/s44313-026-00153-2

BibTeX
@article{Han2026,
  author = {Han, Jae Joon and Lee, Jeong-Ok and Kim, Kyoung Ha and Lee, Sung-Eun and Sohn, Sang Kyun and Jung, Chul Won and Kim, Hawk and Korean Society of Hematology Chronic Myeloid Leukemia Working Party, Korean Society of Hematology Chronic Myeloid Leukemia Working Party},
  title = {Asciminib as first-line therapy in chronic myeloid leukemia: a systematic review},
  journal = {Blood Research},
  year = {2026},
  volume = {61},
  number = {1},
  doi = {10.1007/s44313-026-00153-2}
}
Kostenlos starten →